|
| |
GlaxoSmithKline
| Headquarters location: 980 Great West Road TW8 9GS Brentford Middlesex |  | Tel. 44-20 8047 5000 Job offers, investor relations: www.gsk.com Email: anita.e.kidgell@gsk.com Stock:  |
|
GlaxoSmithKline belongs to |
| shareholder | country % source |
|
|
name  items photo compare the prices |
Shop local, ethical and at the best price on Ethishop ! |
|
|
|
|
| Job: 9% of company's jobs cut since 1998 |
| Environment: 1 major pollution(s) |
| Delinquency: 13 act(s) of financial or trade delinquency |
| Tax haven, secret bank account, shell companies: operates in 7 offshore financial center(s) |
| Sales: more than 13 billion(s) dollars/euros in annual sales |
| Net profit: more than 3 billion(s) dollars/euros in cumulated net profit since 1998 |
| Top management: earns 60 times the median income in the United States (32000 US$/year) |
| Influence: 8 act(s) of direct corruption or lobbying |
| Advertising & marketing: 6 dubious practice(s) |
|
|
Relevance: business & market share |
World locations & Manufacturing |
GlaxoSmithKline is managed by |
| year name | photo position; compensation source |
|
year | dubious practice : image source |
| 2007 | Disinformation: In early September, "major newspapers reported the alarming news that suicides among young people were on the rise because of a precipitous drop in the use of antidepressants," writes Alison Bass. The academic study the news articles were based on concluded that new safety warnings for young people using antidepressant drugs had discouraged doctors from writing prescriptions for depressed youths. But there's a hole in that argument: "while there was indeed an upturn in suicide rates among youths ... the number of prescriptions for antidepressants in the same age group remained basically unchanged." Bass points out that the pharmaceutical companies that make antidepressants might "benefit from the latest alarm about an apparent upturn in youth suicide rates. ... These companies have an enormous stake in reversing the current FDA warnings." Pfizer, which makes the antidepressant Zoloft, did provide $30,000 for the academic study, and the study's lead authors have ties to Pfizer, GlaxoSmithKline and Wyeth Pharmaceuticals. "This isn't the first time that suicide rates have been trotted out as a public relations weapon," Bass adds. "Proponents of psychotropic drugs have long argued that suicide rates ... fell after" such drugs were introduced, though the decline began well before the drugs were widely prescribed.: | Boston Glo.  |
| 2005 | Disinformation: In Fall 2005, the company will begin "an extensive state-by-state media blitz," paralleling its "grassroots outreach." PR Week reported, "Glaxo will target local media markets in each state - outlets that do not often have the chance to communicate directly with pharmaceutical executives." GSK's Pucci said that local reporters were easier for the drug company to deal with. "These folks are hungry for news," he said. "They'll print everything we say … without the political spin." GSK hired two PR firms for the media work, but declined to name them.: | Sourcewatc. |
| 2005 | slogan: Do more, feel better, live longer.; |  |
| 2005 | Soutient l'exposition « Valda toujours » au musée des Arts Décoratifs - Musée de la Publicité de Paris où seront rassemblées des publicités originales sous forme d’affiches, de plaques émaillées et d’automates.: value: Culture; | |
| 2005 | Disinformation: Voyage gratuit pour une trentaine de journalistes français pour se familiariser avec le traitement de l'asthme au Québec: public relations: V | Cyberpress. |
| 2004 | Disinformation: In March 2004, the Canadian Medical Association Journal published excerpts from a GSK "internal document" that advised staff "to withhold clinical trial findings in 1998 that indicated the antidepressant paroxetine (Paxil in North America and Seroxat in the UK) had no beneficial effect in treating adolescents." The GSK memo recommended, in part, that the company needed to "effectively manage the dissemination of these data in order to minimize any potential negative commercial impact" and stated that "It would be commercially unacceptable to include a statement that efficacy had not been demonstrated, as this would undermine the profile of paroxetine.": | Sourcewatc. |
| 2004 | Disinformation: In spring 2004, GSK launched a "grassroots outreach" effort, sending "sales representatives to deliver its message in front of the religious, fraternal, and other community groups to which they belong." A year into the effort, PR Week reported that GSK's standing had improved by 13 points, according to a Harris Interactive poll. "Clearly the grassroots campaign is having an impact," said Michael Pucci, Glaxo's VP of external advocacy.: | Sourcewatc. |
| 2002 | Disinformation: Euro RSCG Vitesse: public relations: E | CB-News |
|
|
| year | employees <> | social impact : country source |
| 2004 | 100019 -100 | |  |
| 2001 | 100000 | | |
| 1999 | 110000 | | |
|
| year | country : consequences source |
| 2004 | United States of America brand: Paxil : Avait versé 2,5 millions de dollars pour mettre fin aux poursuites de la FDA pour avoir caché les risques que présente l'anti-dépresseur Paxil administré à des enfants et adolescents. | Le Revenu |
|
| year | donator | country | amount | source |
|
| year | financial misdemeanor | sales | income | | buyback | source |
| 2006 |
| 45.5 | 8.75 | | | billion US$ | |
| 2006 |
GlaxoSmithKline is fined 10 millions euros for "predatory pricing" by the French Commission on competition. GlaxoSmithKline sold the generic version of the Zinnat antibiotic at prices lower than its own purchase prices, in order to evict other manufacturers such as Flavelab which was selling similar generics. After Flavelab was driven out of the market, GlaxoSmithKline appreciably raised its prices over the two years which followed, recovering very largely the losses authorized for the period of predation. |
| | | | | | Les Echos |
| 2005 |
| 37.27 | 5.74 | | | billion US$ | |
| 2005 |
GSK a payé 150 millions de dollars pour solder à l'amiable un différend portant sur des accusations du gouvernement américain, selon lesquelles il aurait pratiqué des prix élevés et frauduleux sur deux de ses médicaments. |
| | | | | | Les Echos |
| 2005 |
Sued by the State of California for defrauding the state's $34 billion Medi-Cal program by inflating prices. "We're going to drag these drug companies into courts of law because they've been gouging the public," California Attorney General Bill Lockyer said at a news conference. For example, Medi-Cal paid $804.70 US for a bottle of the hypertension drug Atenolol. Providers such as doctors, clinics and pharmacists paid $33.85 US. As a result, providers reimbursed by Medi-Cal for Atenolol pocketed $770.85 US. The windfalls gave doctors, pharmacies and other providers an incentive to prescribe such drugs, which resulted in even more sales by drug makers, Lockyer said. |
| | | | | | Bloomberg |
| 2005 |
A federal judge has granted final approval to SmithKline Beecham's $65 million settlement of a class action antitrust suit brought by consumers who said they paid inflated prices for Paxil, a popular anti-depressant drug. The suit alleged that SmithKline illegally maintained a monopoly by filing a series of "sham" patent lawsuits that were designed to delay any generic version of the drug from reaching the market. Glaxo settles the suit for 14 million dollars. |
| | | | | | Reuters |
| 2004 |
Charged by the US IRS with underpaying taxes of $US 5.2 billion on US profits earned between 1989 and 1996. |
| 39.22 | 5.26 | | | billion US$ | |
| 2004 |
Agreed to pay $92 million to settle antitrust cases involving the antibiotic product Augmentin. |
| | | | | | Bizjournal. |
| 2004 |
Glaxo is facing fraud claims for suppressing at least four different studies showing that Paxil was no more effective than a placebo and at worst was harmful, while promoting heavily the drug boasting of its efficacy and safety. |
| | | | | | The Guardi. |
| 2004 |
Une centaine d'employés de GSK poursuivis pour corruption et associations de malfaiteurs et soupçonnées d'être impliquées dans un système de corruption mis en place par la branche italienne du géant pharmaceutique britannique. |
| | | | | | France 2 |
| 2003 |
| 21.44 | 4.48 | | 0.836 | billion UK£ | |
| 2003 |
Surfacturation: a changé le nom de ses médicaments pour les écouler plus cher à l'administration fédérale états-unienne: amende de 89 millions de $US. |
| | | | | | L'Expansio. |
| 2002 |
| 21.21 | 3.92 | | | billion Eu€ | |
| 2002 |
Evidence of a nationwide "bribery system" in which doctors allegedly prescribed 7-8% more Glaxo products each year in return for "freebies" such as Caribbean trips, stereo systems and wine. |
| | | | | | The Guardi. |
| 2002 |
1600 doctors across Germany are under investigation for allegedly taking bribes such as free holidays in exchange for prescribing Glaxo drugs |
| | | | | | Financial . |
| 2001 |
| 29.84 | 4.5 | | | billion US$ | |
| 2000 |
| 18.08 | 0.07 | | | billion Eu€ | |
| 1999 |
| 25.8 | | | | billion Eu€ | |
| 1995 |
Allegedly bribed Italian health ministry officials |
| | | | | | The Guardi. |
|
|
|
|
Also announce a documentary, a book or an article or comment this company profile.
Goal: present the company activities, improve the ethical rating's accuracy, develop an network of observers.